Evidence map›Paper›PMID 40363788›Full record

ReviewMolecules (Basel, Switzerland)2025

Mechanistic Advances in Hypoglycemic Effects of Natural Polysaccharides: Multi-Target Regulation of Glycometabolism and Gut Microbiota Crosstalk.

Liquan Zhou, Jiani Li, Chen Ding, Yimiao Zhou, Zuowei Xiao

Abstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Metabolites · 2026
    Review
  6. Article
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Liquan ZhouHomologous Innovation Laboratory of Medicine and Food, Hunan University of Chinese Medicine, Changsha 410208, China.ORCID 0009-0001-5022-8316
Jiani LiHomologous Innovation Laboratory of Medicine and Food, Hunan University of Chinese Medicine, Changsha 410208, China.ORCID 0009-0003-1982-4034
Chen DingHomologous Innovation Laboratory of Medicine and Food, Hunan University of Chinese Medicine, Changsha 410208, China.ORCID 0009-0004-7264-8292
Yimiao ZhouHomologous Innovation Laboratory of Medicine and Food, Hunan University of Chinese Medicine, Changsha 410208, China.
Zuowei XiaoHomologous Innovation Laboratory of Medicine and Food, Hunan University of Chinese Medicine, Changsha 410208, China.ORCID 0009-0002-0289-2885

Funding

2022 Annual Natural Drug Resources and Function Development Fund Project 2022ZYYGN06Hunan Natural Science Foundation 2024JJ8163Key Project of Hunan Provincial Administration of Traditional Chinese Medicine 201923Key Project of Hunan Provincial Administration of Traditional Chinese Medicine C2023005
6 · The paper itself

Abstract

Natural polysaccharides (NPs), as a class of bioactive macromolecules with multitarget synergistic regulatory potential, exhibit significant advantages in diabetes intervention. This review systematically summarizes the core hypoglycemic mechanisms of NPs, covering structure-activity relationships, integration of the gut microbiota-metabolism-immunity axis, and regulation of key signaling pathways. Studies demonstrate that the molecular weight, branch complexity, and chemical modifications of NPs mediate their hypoglycemic activity by influencing bioavailability and target specificity. NPs improve glucose metabolism through multiple pathways: activating insulin signaling, improving insulin resistance (IR), enhancing glycogen synthesis, inhibiting gluconeogenesis, and regulating gut microbiota homeostasis. Additionally, NPs protect pancreatic β-cell function via the nuclear factor E2-related factor 2 (Nrf2)/Antioxidant Response Element (ARE) antioxidant pathway and Toll-like receptor 4 (TLR4)/nuclear factor-κB (NF-κB) anti-inflammatory pathway. Clinical application of NPs still requires overcoming challenges such as resolving complex structure-activity relationships and dynamically integrating cross-organ signaling. Future research should focus on integrating multi-omics technologies (e.g., metagenomics, metabolomics) and organoid models to decipher the cross-organ synergistic action networks of NPs, and promote their translation from basic research to clinical applications.

Indexed as

Gastrointestinal MicrobiomeHypoglycemic AgentsPolysaccharidesAnimalsGlucoseHumansInsulin ResistanceSignal TransductionGlucoseHypoglycemic AgentsPolysaccharidesgut microbiotahypoglycemiamechanism of actionnatural polysaccharidessignaling pathway

Identifiers

PMID40363788
PMCPMC12073636

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.